Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Durvalumab
Sponsor:   Samsung Medical Center
Recruiting

http://ift.tt/2yYbz0b